MOTS-c

16-amino-acid peptide encoded by the mitochondrial genome (12S rRNA region). Activates AMPK via folate-cycle inhibition - the same master switch metformin and training adaptation hit. Notorious for a stinging injection.

Research chemicalNot WADA-listedInjectableMetabolicMitochondrial

Key facts

Common routesSC

Half-lifeVery short (plasma); effect tail longer

Typical range5–10 mg/week

Résumé

MOTS-c is a 16-amino-acid peptide not encoded in the nuclear genome but in the mitochondrial one - specifically in the 12S rRNA region. That places it in the mitochondrial-derived peptide (MDP) class, signalling molecules that act between the mitochondria and the cell nucleus. Functionally: a stress signal from the energy-production machinery to the genomic-regulation layer.

The popular framing is “exercise in a bottle.” The science is subtler: MOTS-c inhibits the folate cycle, accumulating AICAR, which directly activates AMPK - the same metabolic master switch metformin and exercise hit. The mouse data is robust (Lee 2015, Reynolds 2021); human data is limited to a modified analog (CB4211, CohBar) for NAFLD, not the raw peptide.

Notes sur le mécanisme

AMPK activation

MOTS-c inhibits the one-carbon folate cycle, leading to AICAR accumulation. AICAR is a direct AMPK activator. AMPK is the cellular energy sensor: turn it on and the cell shifts toward fat oxidation, mitochondrial biogenesis, and insulin sensitivity. The endpoint is the same as metformin or sustained endurance training, just reached via a different upstream path.

Nuclear translocation

Under metabolic stress MOTS-c relocates to the nucleus and interacts with transcription factors like NRF2 to upregulate antioxidant and metabolic genes. That's the “direct memo from mitochondria to genome” mechanism that drives the unusual narrative around this peptide class.

The sting problem

MOTS-c is notorious for a burning, stinging injection reaction - not an allergy, a property of the peptide itself (pH and structure). The only practical countermeasures: warm the vial to body temperature before injection, push slowly, dilute in more bacteriostatic water than standard peptides. Users who skip these adjustments abandon protocols early.

Dosing patterns

Weekly bolus (most common)

5–10 mg SC once weekly. Because of the injection reaction, most users prefer a single large weekly dose over daily pinning. The AMPK metabolic effects persist longer than plasma half-life suggests - the signalling cascade, not direct peptide presence, drives the outcome.

Daily microdose (for high-tolerance users)

1–2 mg SC daily, more closely mimicking constant training-signal patterns. Requires high tolerance for the stinging discomfort; in practice few users sustain this over multiple weeks.

Training timing

Dosed before endurance work, MOTS-c synergises with the natural AMPK activation that exercise produces. Users operating in the endurance space report subjective effects most consistently in this configuration. Pure rest-day dosing produces a subtler signal.

Aperçu des données

Tier: Preclinical. Rating C - solid mouse data and mechanistic clarity; human data exists only via the modified analog (CB4211), not the raw peptide. The “exercise mimetic” narrative is mechanistically defensible, but human body-composition and endurance outcome data are anecdotal.

Human data

CohBar ran Phase 1a/1b trials with the MOTS-c analog CB4211 in NAFLD / obese subjects. Safety was acceptable; biomarker trends pointed toward reduced liver fat and improved liver-health markers. Used an optimised analog, not generic MOTS-c - translatability to grey-market peptide is not 1:1.

Animal data

Lee 2015: MOTS-c-treated mice were protected against diet-induced obesity and insulin resistance; age-related physical decline was prevented. Reynolds 2021: older mice showed significantly improved running capacity and grip strength, comparable to young mice. Mechanism reproducibly confirmed across multiple labs.

Considérations de sécurité

Safety profile appears clean based on endogenous nature and the CohBar Phase 1 safety readout. The only consistent adverse event is the injection reaction (burning, occasional welt). AMPK activation is generally associated with tumour suppression - the theoretical cancer-risk vector is reversed compared to BPC / TB-500. Active cancer is still listed as a caution, however, because altering cellular metabolism in a tumour-active context is complex.

Common cautions

Stinging / burning reaction is expected and not an allergy - countermeasures are required, not optional
Human data is limited to the CB4211 analog - don't extrapolate 1:1 to raw MOTS-c
Active cancer is a caution (theoretical), despite the AMPK tumour-suppression profile
Concurrent metformin: theoretical additive glucose-lowering - bloodwork is the sentinel